RT Journal Article
SR Electronic
T1 Metabolomic fingerprinting in the identification of biomarkers in COPD patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P1436
VO 40
IS Suppl 56
A1 Felipe Villar-Álvarez
A1 Antonia García-Fernández
A1 Alessia Ferrarini
A1 Julio Gómez-Seco
A1 Marcel Rodríguez-Guzmán
A1 Jesús Ruiz-Cabello
A1 Coral Barbas-Arribas
A1 Germán Peces-Barba
YR 2012
UL http://erj.ersjournals.com/content/40/Suppl_56/P1436.abstract
AB INTRODUCTION:Metabolomics fingerprinting is able to achieve the identification of novel biomarkers the comprehensive characterization of the entire metabolome of a disease. The main objective is to use it to understand the pathological basis underlying COPD and its relationship to the severity and phenotypic characteristics.METHODS:Observational case-control study involving COPD patients and controls without COPD or cardiovascular history. COPD patients were grouped in chronic bronchitis and emphysema, and at different stages of GOLD. Different platforms are required to capture all metabolites in one sample of plasma and separation techniques such as gas chromatography coupled to mass spectrometry (GC-Q-MS).RESULTS:This study involved 48 participants; 32 COPD patients (22 men, 10 women) and 20 healthy controls (7 men, 9 women). Mean age: 58,3 and 56,6 respectively. Mean FEV1 value was 64,3%. We can not establish significant differences between COPD and controls in the total population. In women, we can differentiate COPD from the controls by metabolites such as glycolic acid, although its origin is uncertain and could be related to medication. This metabolite, in women, also helps to differentiate emphysema (and smokers) from controls, emphysema and chronic bronchitis from controls and smokers from non smokers. With oxalic acid we can differentiate chronic bronchitis (and smokers) from controls in women, and emphysema from chronic bronchitis in men with COPD (and former smokers). Besides, in this last group, we can differentiate GOLD I from GOLD II with myristic acid.CONCLUSION:Using metabolomic fingerprinting in plasma we could identify markers and differentiate phenotypes and early stages in COPD.